A secure, collaborative platform built by scientists for scientists.
Bridge Analytics connects fragmented research data to accelerate breakthroughs that deliver meaningful clinical advancements for patients with Parkinson's, bipolar disorder, autism, and other central nervous system (CNS) conditions.
Our team tackles big challenges in neuroscience and drives progress in fundamental discovery, biomarker development, therapeutics, and assistive technology. We combine expert scientific consultation with the Bridge Analytics Environment—a secure, collaborative platform built by scientists for scientists. By turning complex data science into actionable insights, we empower research teams to make the high-impact decisions that drive discovery and therapeutic advances.
Accelerate breakthroughs in central nervous system conditions by directly connecting data to the decisions that move the field forward.
To serve as the data intelligence layer for global CNS progress, ensuring collective knowledge and strategic expertise accelerate the delivery of life-changing therapies.
The development of therapeutic solutions for CNS conditions will take more than any one team can do alone. It will take all of us—doctors, clinicians, researchers, data scientists, and data engineers—working together against a shared set of goals. That collaboration becomes impossible without the right data strategy and supporting infrastructure.
We make it easy to find, access, and analyze the data collected across CNS research initiatives. More than just a data repository—we ensure that the power to analyze lives alongside the data, letting researchers get to answers more quickly.
We enable people with deep biological and clinical expertise to partner with experts in quantitative analytic approaches and execute targeted research projects.
Dr. Ritu Kapur is a systems neuroscientist with over 18 years of experience in neurodegenerative disease, medical device development, neuromodulation, and signal processing. She has built teams and developed products that leverage traditional and machine-learning methods to extract clinically relevant information from high-density datasets. Most recently, Ritu founded and led Digital Biomarkers at Verily, a team of over 100 scientists, engineers, and operations professionals.
Dr. Ritu Kapur is a systems neuroscientist with over 18 years of experience in neurodegenerative disease, medical device development, neuromodulation, and signal processing. She has built teams and developed products that leverage traditional and machine-learning methods to extract clinically relevant information from high-density datasets. Most recently, Ritu founded and led Digital Biomarkers at Verily, a team of over 100 scientists, engineers, and operations professionals.
Dr. Ritu Kapur is a systems neuroscientist with over 18 years of experience in neurodegenerative disease, medical device development, neuromodulation, and signal processing. She has built teams and developed products that leverage traditional and machine-learning methods to extract clinically relevant information from high-density datasets. Most recently, Ritu founded and led Digital Biomarkers at Verily, a team of over 100 scientists, engineers, and operations professionals.
Dr. Ritu Kapur is a systems neuroscientist with over 18 years of experience in neurodegenerative disease, medical device development, neuromodulation, and signal processing. She has built teams and developed products that leverage traditional and machine-learning methods to extract clinically relevant information from high-density datasets. Most recently, Ritu founded and led Digital Biomarkers at Verily, a team of over 100 scientists, engineers, and operations professionals.
Dr. Ritu Kapur is a systems neuroscientist with over 18 years of experience in neurodegenerative disease, medical device development, neuromodulation, and signal processing. She has built teams and developed products that leverage traditional and machine-learning methods to extract clinically relevant information from high-density datasets. Most recently, Ritu founded and led Digital Biomarkers at Verily, a team of over 100 scientists, engineers, and operations professionals.
.jpg)
.png)
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Bridge Analytics is part of the CNS Quest, an initiative to accelerate discoveries, advance treatments and care, and improve the daily lives of people impacted by Parkinson's disease, autism, bipolar disorder, and other CNS conditions—shortening the journey from lab to living well. The CNS Quest is a program of the Sergey Brin Family Foundation and Catalyst4.
Learn more
-01.png)
